Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Leukemia, Myeloid, Acute 51Leukemia 26Myelodysplastic Syndromes 10Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 9Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Congenital Abnormalities 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Blast Crisis 5Anemia, Refractory, with Excess of Blasts 5Recurrence 4Leukemia, Promyelocytic, Acute 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Liver Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Leukemia, Basophilic, Acute 3Carcinoma, Hepatocellular 3Myeloproliferative Disorders 2Lung Neoplasms 2Graft vs Host Disease 2Thrombocythemia, Essential 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Polycythemia Vera 1Neutropenia 1

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × Idarubicin × Clear all
NCT02185768 2025-07-04

IDASPHERE II

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
46 enrolled 11 charts
Gastrointestinal

Liver Neoplasms

NCT06492408 2024-07-09

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06482801 2024-07-01

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡